Inflammation  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

109 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT01459913 / 2011-001323-21: Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Checkmark HepDART 2013: CONCISE
Dec 2013 - Dec 2013: HepDART 2013: CONCISE
Checkmark EASL 2013: CONCIZE
Apr 2013 - Apr 2013: EASL 2013: CONCIZE
Terminated
3b
239
US, Canada, Europe, RoW
Telaprevir, INCIVEK, INCIVO, VX-950, Pegylated Interferon Alfa-2a, Pegasys, Peg-IFN-Alfa-2a, Ribavirin, Copegus, RBV
Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
01/14
01/14
PEGARI, NCT00221624: Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients

Completed
3
131
Europe
Peginterferon alfa-2a, ribavirin, amantadine
University Hospital, Bordeaux, Hoffmann-La Roche
HCV Infection, Hepatitis C, Chronic
 
04/04
NCT00048945: Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Completed
3
820
US, Canada, Europe, RoW
PEGASYS
Hoffmann-La Roche
Chronic Hepatitis B
10/04
10/04
NCT00038974: Hepatitis C Antiviral Resistance in African-Americans

Completed
3
401
US
peginterferon alfa-2a, Ribavirin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), Hoffmann-La Roche
Hepatitis C
12/04
11/05
NCT00158496: Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Completed
3
100
RoW
pegylated interferon alpha2a, ribavirin
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
Chronic Hepatitis C
 
01/05
NCT00381953: High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Completed
3
33
Europe
Peginterferon alfa-2a, Pegasys, Interferon alfa-2a, Intron-A, Ribavirin, Copegus
Foundation for Liver Research
Hepatitis C
04/06
07/06
NCT00466219: Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant

Completed
3
25
Europe
Ribavirin, Pegylated interferon alpha2a
University Hospital, Geneva
Hepatitis C
 
12/06
NCT00221286: Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Terminated
3
2
Europe
pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy
University Hospital, Bonn, Hoffmann-La Roche
Chronic Hepatitis B, HIV Infections
01/07
01/07
NCT00299923 / 2005-001207-19: Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Unknown status
3
300
Europe
Peginterferon alfa-2a, Ribavirin, Amantadine
University of Hamburg-Eppendorf, Universitätsklinikum Hamburg-Eppendorf, Hoffmann-La Roche
Hepatitis C, Chronic, Relapse
 
 
HALT-C, NCT00006164: Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Checkmark EASL 2013: HALT-C
Apr 2013 - Apr 2013: EASL 2013: HALT-C
Completed
3
1050
US
Peginterferon alfa-2a + Ribavirin, Pegasys (Hoffman-La Roche), Copegus (Hoffman-La Roche), Peginterferon alfa-2a
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), Hoffmann-La Roche
Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
04/07
10/09
NCT00296972: Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

Terminated
3
100
Canada
peg interferon plus ribavirin
University Health Network, Toronto, Hoffmann-La Roche
Chronic Hepatitis C, HIV Infections
 
04/07
NCT02806505: HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Completed
3
81
Europe, RoW
Peginterferon alfa-2a, Pegasys
Hoffmann-La Roche
Hepatitis C, Chronic
08/07
08/07
NCT00154869: Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Unknown status
3
320
RoW
Peginterferon Alfa-2a plus Ribavirin
National Taiwan University Hospital, Hoffmann-La Roche
Hepatitis B, Chronic, Hepatitis C, Chronic
 
08/07
NCT00081770: Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Completed
3
4469
NA
PegIntron (peginterferon alfa-2b; SCH 54031), PegIntron, REBETOL (ribavirin; SCH 18908), REBETOL [the Schering-Plough brand name for ribavirin], PEGASYS (peginterferon alfa-2a), PEGASYS, COPEGUS (ribavirin), COPEGUS [the Hoffman-La Roche brand name for ribavirin]
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
11/07
11/07
NCT00158522: Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

Completed
3
31
RoW
pegylated interferon alpha2a
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
Hepatitis C
12/07
12/07
NCT01178996 / 2004-001277-25: Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Completed
3
552
Europe
Thymosin alpha 1, Zadaxin, Ribavirin, Copegus, PEGinterferon alfa2a, Pegasys, Placebo
sigma-tau i.f.r. S.p.A., SciClone Pharmaceuticals
Chronic Hepatitis C
05/08
07/09
NCT02791256: A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Terminated
3
23
Europe
Ribavirin, Copegus, Ro 20-9963, peginterferon alfa-2a, Pegasys, Ro 25-8310
Hoffmann-La Roche
Hepatitis C, Chronic
06/08
06/08
NCT00441584: The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Terminated
3
117
NA
PegIntron (peginterferon alfa-2b), SCH 54031, PEG-Intron, PegIntron, ViraferonPeg, peginterferon alfa-2b, Rebetol (ribavirin), SCH 18908, Rebetol, REBETOL, ribavirin
Merck Sharp & Dohme LLC, Integrated Therapeutics Group
Hepatitis C, Chronic
06/08
06/08
CIPPAD, NCT00136318: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Completed
3
208
Europe
Escitalopram, Placebo, Peginterferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin
Charite University, Berlin, Germany
Depression
09/08
09/08
NCT02732639: A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Completed
3
31
Europe
Pegylated Interferon (PEG-IFN) alfa-2a, PEGASYS
Hoffmann-La Roche
Hepatitis D, Chronic
12/08
12/08
NCT00412750: Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Terminated
3
159
US
Telbivudine (LdT), Sebivo, peginterferon alpha-2a, Pegasys
Novartis
Hepatitis B
02/09
02/09
NCT00122616: Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

Completed
3
52
Europe
Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
HIV Infections, Hepatitis C, Chronic
03/09
03/09
PERFECT, NCT02762383: Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial

Terminated
3
19
Europe
Peginterferon Alfa-2, Pegasys
Hoffmann-La Roche
HIV/HCV Coinfection
06/09
06/09
NCT00336518 / 2005-004531-22: Continuing Treatment With Pegasys and Copegus

Unknown status
3
100
Europe
peginterferon alfa-2a, ribavirin
Májbetegekért Alapítvány, Hoffmann-La Roche
Chronic Hepatitis C
 
07/09
NCT01237496 / 2005-000336-25: Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Completed
3
17
Europe
peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis B, Chronic
09/09
09/09
MASTER, NCT01296971: A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C

Withdrawn
3
0
RoW
peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
12/09
12/09
NCT01095835 / 2004-002985-39: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Completed
3
131
Europe
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegasys®, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM)
Hoffmann-La Roche
Hepatitis B, Chronic
01/10
01/10
NCT00483938: The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

Completed
3
236
US, Canada
Pegylated-interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
05/10
05/10
NCT00627926 / 2007-004720-20: A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Checkmark REALIZE & ADVANCE
Mar 2014 - Mar 2014: REALIZE & ADVANCE
Checkmark AASLD 2013: OPTIMIZE & ADVANCE HEOR data
Oct 2013 - Oct 2013: AASLD 2013: OPTIMIZE & ADVANCE HEOR data
Checkmark ADVANCE - HRQL data
More
Completed
3
1095
US, Canada, Europe, RoW
Pegylated Interferon Alfa 2a, Pegasys, Peg-IFN-alfa-2a, Telaprevir, VX-950, Ribavirin, Copegus, RBV, Placebo
Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited
Hepatitis C
05/10
05/10
NCT00758043 / 2008-003836-39: A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Checkmark Data-AASLD
Oct 2011 - Oct 2011: Data-AASLD
Checkmark Data
Sep 2011 - Sep 2011: Data
Completed
3
540
Europe, US
telaprevir, VX-950, ribavirin, Copegus, peginterferon alfa-2a, Pegasys
Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited
Hepatitis C
06/10
07/10
NCT00703118: A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Checkmark REALIZE
Jun 2014 - Jun 2014: REALIZE
Checkmark EASL 2014: REALIZE & HEP3002
Mar 2014 - Mar 2014: EASL 2014: REALIZE & HEP3002
Checkmark REALIZE & ADVANCE
More
Completed
3
663
US, Canada, Europe, RoW
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Tibotec BVBA, Tibotec Pharmaceutical Limited
Hepatitis C, Chronic
07/10
07/10
2008-000533-22: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment.

Completed
3
650
Europe, RoW
telaprevir, Pegasys, Copegus, VX-950, Tablet, Solution for injection, Pegasys, Copegus
Tibotec BVBA, TIBOTEC BVBA
Chronic genotype 1 Hepatitis C infection
 
 
NCT00845065 / 2008-004760-39: Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Checkmark P3 data
Mar 2012 - Mar 2012: P3 data
Completed
3
202
NA
Boceprevir, SCH 503034, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, SCH 18908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
10/10
10/10
ADVANCE, NCT00661076: Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Completed
3
10
RoW
adefovir dipivoxil, peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis B, Chronic
05/11
05/11
NCT01853254: A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Completed
3
272
US, Europe, RoW
Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
09/11
09/11
2004-001718-15: An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipated in previous Roche protocols.

Completed
3
750
Europe
peginterferone alfa-2A, Solution for injection, Film-coated tablet, L03AB11-Peginterferone alfa-2A, J05AB04 - Ribavirina - Copegus 168 cpr riv 200mg
ROCHE, F. Hoffmann-La Roche Ltd
chronic hepatitis C
 
 
NCT00800735 / 2008-002022-10: A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Completed
3
30
US, Canada, Europe
Pegylated-interferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin, Copegus, Ro 20-9963
Hoffmann-La Roche
Hepatitis C, Chronic
03/12
03/12
NCT01054573 / 2009-012613-21: VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Checkmark EASL 2013: VX-950-TiDP24-C219
Apr 2013 - Apr 2013: EASL 2013: VX-950-TiDP24-C219
Checkmark Data-AASLD
Nov 2011 - Nov 2011: Data-AASLD
Completed
3
90
US, Canada, Europe, RoW
Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
Janssen Infectious Diseases BVBA, Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
03/12
05/12
NCT00623428 / 2007-004993-15: A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Completed
3
235
US, Canada, Europe, RoW
peginterferon alfa-2a, Pegasys®, PEG-IFN alfa-2a, Ribavirin, Copegus®
Hoffmann-La Roche
Hepatitis C, Chronic
05/12
05/12
NCT01500772 / 2011-004653-31: Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Terminated
3
6
US, Canada, Europe
Alisporivir, DEB025, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, RBV
Debiopharm International SA
Hepatitis C
05/12
05/12
NCT01290731: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Checkmark CONCERTO-2 and CONCERTO-3
Mar 2014 - Mar 2014: CONCERTO-2 and CONCERTO-3
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
49
Japan
TMC435, Pegylated interferon (pegIFN alpha-2a), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
08/12
08/12
NCT01288209: A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Checkmark CONCERTO-2 and CONCERTO-3
Mar 2014 - Mar 2014: CONCERTO-2 and CONCERTO-3
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
106
Japan
TMC435, Peginterferon alfa-2a (PegIFNα-2a ), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
09/12
09/12
NCT01292239: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Checkmark CONCERTO-1
Apr 2014 - Apr 2014: CONCERTO-1
Checkmark APASL 2014: CONCERTO studies
Mar 2014 - Mar 2014: APASL 2014: CONCERTO studies
Checkmark CONCERTO studies
More
Completed
3
183
Japan
Placebo, TMC435, Peginterferon alfa-2a (pegIFN alfa-2a), PEGASYS, Ribavirin (RBV), COPEGUS
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
10/12
10/12
NCT01892241: Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Completed
3
74
RoW
Pegasys(Roche), peginterferon alfa-2a, Entecavir
Third Affiliated Hospital, Sun Yat-Sen University
Antiviral Treatment of Chronic Hepatitis B
11/12
02/13
2004-004848-45: HCV/HIV Coinfection- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV -COINFECTION

Completed
3
80
Europe
Pegasys 180 Mikrogramm, Copegus 200 mg, Solution for injection, Film-coated tablet, Pegasys 180 Mikrogramm Injektionslösung in einer Fertigspritze, Copegus 200 mg - Filmtabletten
Medizinische Universität Wien
HIV/HCV - Coinfection
 
 
QUEST-1, NCT01289782 / 2010-020444-36: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark QUEST-1
Jun 2014 - Jun 2014: QUEST-1
Checkmark EASL 2014: QUEST 1 & QUEST 2
More
Completed
3
395
US, Canada, Europe, RoW
Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen R&D Ireland
Hepatitis C
01/13
01/13
NCT01497366 / 2011-005055-14: Phase 3 Study of Sofosbuvir and Ribavirin

Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
Mar 2014 - Mar 2014: EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
More
Completed
3
527
US, Canada, Europe, RoW
Sofosbuvir, Sovaldi™, GS-7977, PSI-7977, PEG, Pegasys®, RBV
Gilead Sciences
Hepatitis C
01/13
04/13
NEUTRINO, NCT01641640: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Checkmark FUSION, NEUTRINO & VALENCE
Apr 2014 - Apr 2014: FUSION, NEUTRINO & VALENCE
Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark DDW 2014: FUSION & NEUTRINO
More
Completed
3
328
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV, Ribasphere®, PEG, PEGASYS®
Gilead Sciences
Chronic Hepatitis C
01/13
04/13
PROMISE, NCT01281839 / 2010-021113-23: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark BWG 2014: PROMISE
Aug 2014 - Aug 2014: BWG 2014: PROMISE
Checkmark BWG 2014: PROMISE
More
Completed
3
394
US, Canada, Europe, RoW
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen R&D Ireland
Hepatitis C
02/13
02/13
QUEST-2, NCT01290679 / 2010-021174-11: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark QUEST-2
Jun 2014 - Jun 2014: QUEST-2
Checkmark EASL 2014: QUEST 1 & QUEST 2
More
Completed
3
393
US, Europe, RoW
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), PegIFNα-2a (Pegasys), PegIFNα-2b (PegIntron), Ribavirin (RBV), Copegus, Rebetol
Janssen R&D Ireland
Hepatitis C
02/13
02/13
VIRID, NCT00662220 / 2007-005344-25: High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4

Terminated
3
110
Europe
ribavirin, Copegus, Pegasys, NeoRecormon
Foundation for Liver Research, Hoffmann-La Roche
Chronic Hepatitis C
06/13
11/13
POTENT, NCT01220596: Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.

Unknown status
3
228
RoW
Entecavir and Pegylated interferon α-2a Sequential Treatment Group, Generic/Brand name: Pegylated interferon α-2a/Pegasys(TM), Generic/Brand name: Entecavir/Baraclude(TM), Pegylated interferon α-2a Monotreatment Group
Hanyang University, Roche Pharma AG
Hepatitis B, Chronic
06/13
06/13
NCT01374308: NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients

Unknown status
3
160
RoW
NASVAC, Pegylated interferon alpha 2b, Pegasys, Pegintron, Pegin, Optipeg, Peghebron
Clinical Research Organization, Dhaka, Bangladesh
Chronic Hepatitis B
06/13
12/13
NCT01697501 / 2012-002777-56: A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253

Completed
3
88
Europe
Interleukin 28B testing
Hoffmann-La Roche
Hepatitis B, Chronic
06/13
06/13
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Active, not recruiting
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals
Hepatitis C Virus Genotype-1
08/13
08/13
NCT01479868: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Checkmark
Sep 2014 - Sep 2014: 
Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Checkmark Primary results of naïve/relapser HIV/HCV co-infected patients at EACS
More
Completed
3
109
US, Canada, Europe
TMC435, Pegylated interferon alpha-2a, Ribavirin
Janssen R&D Ireland
Hepatitis C Virus Genotype-1
08/13
08/13
NCT01389323: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Completed
3
448
US
Daclatasvir, BMS-790052, Peg-Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
09/13
01/14
Hallmark QUAD, NCT01573351 / 2011-005422-21: Phase III ASV+DCV+Peg+Rib (Nulls/Partials)

Completed
3
398
US, Canada, Europe, RoW
Asunaprevir, BMS-650032, Daclatasvir, BMS-790052, Peg-interferon Alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
09/13
12/13
NCT01448044 / 2011-002793-23: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed
3
152
US, Europe
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
10/13
01/14
NCT01581203 / 2011-005446-35: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Checkmark AVHC 2014
Oct 2014 - Oct 2014: AVHC 2014
Checkmark HALLMARK DUAL
Jul 2014 - Jul 2014: HALLMARK DUAL
Checkmark HALLMARK DUAL
More
Completed
3
748
US, Canada, Europe, RoW
Asunaprevir (ASV), BMS-650032, Daclatasvir (DCV), BMS-790052, Pegylated-interferon alfa 2a (PegIFN), Pegasys, Ribavirin (RBV), Copegus
Bristol-Myers Squibb
Hepatitis C Virus
10/13
09/14
COMMAND-3, NCT01492426 / 2011-004237-14: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Checkmark VHC 2014: COMMAND-3
Oct 2014 - Oct 2014: VHC 2014: COMMAND-3
Completed
3
605
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Telaprevir, Incivek®, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C
12/13
03/14
NCT01467479 / 2011-002668-25: A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Terminated
3
185
US, Canada, Europe
Telaprevir, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Vertex Pharmaceuticals Incorporated
Hepatitis C
02/14
02/14
NCT01447394: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Withdrawn
3
0
US, Canada, Europe, RoW
Pegylated Interferon Lambda, BMS-914143, Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Ribasphere
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
03/14
08/14
RESTORE, NCT01567735 / 2011-004097-29: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

Checkmark Presented at BWG 2015
Mar 2015 - Mar 2015: Presented at BWG 2015
Checkmark BWG 2015
Mar 2015 - Mar 2015: BWG 2015
Checkmark AASLD 2014: RESTORE
More
Completed
3
107
Europe
TMC435
Janssen R&D Ireland
Hepatitis C
03/14
03/14
NCT01581398: Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Completed
3
770
RoW
Ypeginterferon alfa-2b, Pegasys
Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis C
04/14
06/14
NCT01471574 / 2011-003067-30: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed
3
549
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Ribavirin, Copegus®, PEG-Interferon alfa 2a, Pegasys®, Pegylated interferon
Bristol-Myers Squibb
Hepatitis C, Genotype 1
06/14
09/14
PRINCIPAL, NCT01616524 / 2011-004885-14: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed
3
880
Japan, US, Europe, RoW
Pegylated interferon lambda (pegIFNλ), BMS-914143, Pegylated interferon alfa-2a (pegIFNα-2a), Pegasys, Ribavirin, Ribasphere, Daclatasvir, BMS-790052, Placebo matching Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
06/14
09/14
NCT01754974 / 2012-003508-11: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Completed
3
40
Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Ribavirin, Ribasphere, Peginterferon alfa-2a, Pegasys
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
09/14
09/14
NCT01718158 / 2011-005409-65: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed
3
444
Japan, US, Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Peginterferon Alfa-2a, Pegasys®, Ribavirin, Copegus®, Daclatasvir, BMS-790052, Telaprevir, Incivek®
Bristol-Myers Squibb
Hepatitis C
10/14
10/14
2014-000453-37: Treatment with association of two drugs (Viread and Pegasys) in patients with hepatitis B. TRATTAMENTO CON ASSOCIAZIONE DI DUE FARMACI (VIREAD E PEGASYS) NEI PAZIENTI AFFETTI DA EPATITE B

Ongoing
3
80
Europe
Viread, Pegasys, Tablet, Solution for injection, Viread, Pegasys
Azienda Ospedaliera di Padova, Azienda Ospedaliera di Padova
Hepatitis B virus (HBV) EPATITE CRONICA HBV-CORRELATA, Chronic liver disease caused by hepatitis B MALATTIA EPATICA CRONICA CAUSATA DAL VIRUS DELL’EPATITE B, Diseases [C] - Virus Diseases [C02]
 
 
PEDESTAL, NCT01598090 / 2011-004695-11: Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Completed
3
881
Europe, Canada, US, RoW
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Pegasys, Ribavirin, Telaprevir, Incivek
Bristol-Myers Squibb
Hepatitis C Virus
02/15
05/15
NCT01769833: HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Unknown status
3
144
RoW
PEG-interferon-Alfa-2A, Pegasys (PEG-interferon-Alfa-2A), Nucleosides
Pusan National University Hospital
Chronic Hepatitis B
05/15
05/16
NCT01544920 / 2011-001345-32: Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Completed
3
737
NA
peg-Interferon alfa-2a, Pegasys™; SCH 054031, Ribavirin, Rebetol™; 018908, Boceprevir, SCH 503034; Victrelis™
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/15
05/15
PEGAN, NCT01172392 / 2010-019367-11: A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

Unknown status
3
185
Europe
Pegylated interferon-alpha-2a, Nucleotidic or Nucleosidic Treatment
ANRS, Emerging Infectious Diseases, Roche Pharma AG
Chronic Hepatitis B, AgHbs Negativation
06/15
06/15
NCT01760122: Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Completed
3
820
RoW
Ypeginterferon alfa-2b, Pegasys
Xiamen Amoytop Biotech Co., Ltd., Peking University First Hospital
Chronic Hepatitis B
07/15
08/15
NCT01519960 / 2011-002732-70: A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Completed
3
165
Europe, US, RoW
peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis B, Chronic
07/15
10/21
NCT01903278: Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Completed
3
719
RoW
PEG-IFN-SA /RBV, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis c
08/15
08/15
NCT01846832 / 2012-004905-29: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Checkmark Data from simeprevir + pegylated interferon alfa-2a + ribavirin 12-week triple combination, open-label, single-arm trial for treatment naïve GT1 hep C infected patients
Mar 2015 - Mar 2015: Data from simeprevir + pegylated interferon alfa-2a + ribavirin 12-week triple combination, open-label, single-arm trial for treatment naïve GT1 hep C infected patients
Completed
3
232
Europe, RoW
TMC435, Pegylated interferon alfa-2a (PegIFNα-2a), Pegasys, Ribavirin (RBV), Copegus
Janssen-Cilag International NV
Hepatitis C, Chronic, Infection
08/15
08/15
2012-004138-41: Can protective T cell responses be improved by telaprevir therapy in patients with chronic hepatitis C who have deeply inhibited HCV-specific T cells? Le risposte proteggenti dei linfociti T possono essere migliorate dalla terapia con telaprevir nei pazienti con infezione cronica C in cui tali risposte sono di base profondamente depresse?

Terminated
3
30
Europe
Tablet, Capsule, Solution for injection, INCIVO, REBETOL*140CPS 200MG, PEGASYS*SC PEN 0,5ML 180MCG
AZIENDA OSPEDALIERA DI PARMA, JANSSEN-CILAG
Chronic active hepatitis C never treated previously with anti-HCV therapies Epatite cronica attiva da virus dell’epatite C (HCV) mai precedentemente sottoposti a terapie anti-virali per HCV, Chronic active hepatitis C never treated previously with anti-HCV therapies Epatite cronica attiva da virus dell’epatite C (HCV) mai precedentemente sottoposti a terapie anti-virali per HCV, Diseases [C] - Virus Diseases [C02]
 
 
NCT01889433: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Completed
3
170
RoW
Algeron, Cepeginterferon alfa-2b, Pegasys, Peginterferon alfa-2a
Biocad
Hepatitis, Hepatitis C
12/15
12/15
2004-004852-38: A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage renal disease undergoing hemodialysis.

Completed
3
30
Europe
L03AB11-Peginterferone alfa -2a interferone alfa -2a pegilato Pegasis sc sir 0,5 135mcg +AG, L03AB11-Peginterferone alfa -2a interferone alfa -2a pegilato Pegasis sc sir 0,5 135mcg +AG
ROCHE
chronic hepatitis C CHC virus infection in patients with end-stage renal disease ESRD undergoing hemodialysis
 
12/08
2005-005161-11: Treatment with leucocytic interferon-alpha more ribavirine towards peg-interferon to reduced doses more ribavirine in patients affections from positive chronic hepatitis HCV that in course of arranged therapy demand the reduction of the peghilato dosage of interferon.

 
3
200
Europe
ALFAFERONE INIET.1F3000000UI, REBETOL 140 CPS 200 MG, PEGASYS 180MCG 1SIR- 1AGO, PEGINTRON 1 FL 100 MCG 1 F, ALFAFERONE INIET.1F3000000UI, REBETOL 140 CPS 200 MG, PEGASYS 180MCG 1SIR- 1AGO, PEGINTRON 1 FL 100 MCG 1 F
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
CHRONIC HEPATITIS FROM VIRUS C
 
 
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon

Ongoing
3
50
Europe
KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS
OSPEDALE S. RAFFAELE
patients affected by HIV and chronic HCV or compensated cirrhosis
 
 
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ

Ongoing
3
60
Europe
KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS
OSPEDALE S. RAFFAELE
PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES
 
 
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.

Ongoing
3
414
Europe
Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus
Charité Universitätsmedizin Berlin
First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV
 
 
2007-005332-83: Combined therapy with Adefovir and Interferon-Pegylated alfa 2a vs Adefovir alone, in patients affected by chronic hepatitis B, HbeAg negative (The PAC (Peg Adefovir Combination) Study).

 
3
100
Europe
HEPSERA, PEGASYS*SC SIR 0,5ML 180MCG+AG, HEPSERA, PEGASYS*SC SIR 0,5ML 180MCG+AG
AZIENDA OSPEDALIERA DI CASERTA
Patients affected by chronic hepatitis B, HbeAg negative
 
 
2008-004761-26: PILOT MULTICENTER OPEN STUDY TO EVALUATE EFFICACY AND TOLERABILITY OF PEG-INTERFERON ALFA-2A IN PATIENTS WITH ANTI-HBE POSITIVE CHRONIC HEPATITIS B WHO PRESENT RESIDUAL VIREMIA OR VIROLOGICAL REBOUND DURING NUCLEOS(T)IDE ANALOGUE TREATMENT

 
3
60
Europe
PEGASYS, PEGASYS
AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA, DEGLI STUDI DI NAPOLI
Patients with chronic hepatitis B, HBeAg-negative, on treatment with nucleos(t)ide analogues.
 
 
2009-013442-86: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Completed
3
18
Europe
GS-9190, GS-9190, Copegus Tablets 200 mg, Pegasys 180 mcg, Copegus Tablets 200 mg, Pegasys 180 mcg
Gilead Sciences Inc
Chronic Hepatitis C Virus Infection
 
12/10
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates

Ongoing
3
100
Europe
Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg
Karolinska University hospital Huddinge
Chronic hepatitis C infection
 
 
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients.

Ongoing
3
110
Europe
Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus
Swedish Orphan International AB
Hepatitis C
 
 
MK-4031-376, NCT01641926: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Terminated
3
402
NA
PEG-Intron™, SCH 054031, Pegylated interferon alfa-2b, PEGASYS™, Pegylated interferon alfa-2a
Merck Sharp & Dohme LLC
Hepatitis B, Chronic
01/16
01/16
PIONEER, NCT03833362: Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 ( - Study)

Completed
3
420
RoW
Narlaprevir, Ritonavir, Norvir, Placebo Narlaprevir, Placebo Ritonavir, Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b, Pegasys, PegIntron, Ribavirin, Rebetol
R-Pharm
Hepatitis C
03/16
02/17
COMMAND-Asia, NCT01797848: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Withdrawn
3
0
RoW
Peginterferon alfa 2a, Pegasys®, Ribavirin, Copegus® (Taiwan, Korea and Singapore), Wei Lining (China), Placebo matching Daclatasvir, Daclatasvir, BMS-790052-05
Bristol-Myers Squibb
Hepatitis C
11/16
11/16
NCT01368497: Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Completed
3
60
Canada, US
Entecavir and peginterferon, PEGASYS, peginterferon alfa 2a, Baraclude
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B
12/16
12/16
NCT01369199: Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Terminated
3
28
Canada, US
Entecavir and peginterferon, PEGASYS, peginterferon alfa 2a, Baraclude
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR)
Hepatitis B
02/17
02/17
NCT01088659: A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Completed
3
50
RoW
peginterferon alfa-2a [Pegasys], placebo, tenofovir
Hoffmann-La Roche
Hepatitis D, Chronic
12/17
12/17
NCT01890200: The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Withdrawn
3
0
RoW
Peginterferon alfa-2a, Pegasys, Ribavirin, Rebetol, TCM-700C, Placebo, Placebo, without acting ingredient.
TCM Biotech International Corp.
Chronic Hepatitis C
03/18
06/18
NCT01380938: Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)

Checkmark EASL data
Apr 2012 - Apr 2012: EASL data
Completed
3
1150
Europe
Peginterferon alpha-2a + Ribavirin, Peginterferon alpha-2a (40 kD) PEGASYS, Copegus or Rebetol, Ribavirin Teva
Casa Sollievo della Sofferenza IRCCS, Casa di Cura Mater Dei, IRCCS L. Spallanzani, Ospedale Francesco Ferrari, Azienda Ospedaliero Universitaria di Sassari, IRCCS Policlinico S. Matteo, Arcispedale S. Anna, Ferrara, Azienda Ospedaliero-Universitaria, Catania, Ospedale di Venosa, Ospedale Monsignor R. Dimiccoli, Barletta, IRCCS De Bellis, Castellana, USL Napoli 1, Ospedale San Giuseppe Moscati, Avellino, Cardarelli Hospital, Ospedale Civile Vittorio Emanuele II, Bisceglie, Azienda Ospedaliero-Universitaria Careggi, Azienda Ospedaliera V. Cervello, Ospedale Civile Spirito Santo, Ospedale di Canosa di Puglia, University of Palermo, San Camillo Hospital, Rome, Campus Bio-Medico University, Ospedale Sandro Pertini, Roma, Ospedali Riuniti di Foggia, Ospedale SS. Annunziata, Taranto, Ospedale di Mottola, Ospedale Santa Caterina Novella, Galatina, University of Florence, Ospedale Valduce, Como, University of Bari, Azienda Ospedaliera, Siracusa, Azienda Ospedaliera, Lucca
Chronic Hepatitis
11/19
11/19
NCT02263079 / 2006-000977-31: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Completed
3
62
Europe, US, RoW
Entecavir, Lamivudine, Pegylated Interferon Alfa-2A, Pegasys, Peg-IFN-Alfa-2A
Hoffmann-La Roche
Pediatric Immuno-Tolerant Chronic Hepatitis B
01/20
01/20
NCT01369212: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Completed
3
201
Canada, US
Tenofovir, Hepatitis B, Viread, Peginterferon-alfa 2a and tenofovir, PEGASYS, tenofovir
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR)
Hepatitis B
03/21
03/21
 

Download Options